Anti-angiogenic agents combined with chemotherapy in the first-line or the second line or combine with EGFR-TKI target therapy in advanced NSCLC have shown significant improvements in the ORR, PFS or OS. This evidence concerns the gene EGFR and non-small cell lung carcinoma.